0001479290-19-000060.txt : 20190510 0001479290-19-000060.hdr.sgml : 20190510 20190510210909 ACCESSION NUMBER: 0001479290-19-000060 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190509 FILED AS OF DATE: 20190510 DATE AS OF CHANGE: 20190510 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Russell Angus C. CENTRAL INDEX KEY: 0001534002 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 19816687 MAIL ADDRESS: STREET 1: C/O INTERMUNE, INC. STREET 2: 3280 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-742-3400 MAIL ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 4 1 wf-form4_155753693463342.xml FORM 4 X0306 4 2019-05-09 0 0001479290 Revance Therapeutics, Inc. RVNC 0001534002 Russell Angus C. C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK CA 94560 1 0 0 0 Common Stock 2019-05-09 4 A 0 4500 0 A 10500 D Stock Option (Right to buy) 12.82 2019-05-09 4 A 0 9000 0 A 2029-05-08 Common Stock 9000.0 9000 D Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 9, 2020, subject to Mr. Russell's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. The shares subject to the stock option shall vest on the one year anniversary, May 9, 2020, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. /s/ Gordon Ho, Attorney-in-Fact 2019-05-10